{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:37:38Z","timestamp":1794584258706,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180672"],"award-info":[{"award-number":["RP180672"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR024574"],"award-info":[{"award-number":["RR024574"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT RP200443"],"award-info":[{"award-number":["CPRIT RP200443"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA125123"],"award-info":[{"award-number":["CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA248478"],"award-info":[{"award-number":["R37CA248478"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.athoracsur.2021.08.054","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T14:43:57Z","timestamp":1632753837000},"page":"1842-1852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Inhibition of Cyclin Dependent Kinase 4\/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma"],"prefix":"10.1016","volume":"114","author":[{"given":"Hee-Jin","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Y.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hudson M.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwari","family":"Ramineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Seog","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Taylor","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2021.08.054_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib5","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98575","article-title":"Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma","volume":"3","author":"Lee","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7816","article-title":"Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment","volume":"11","author":"Zemek","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib14","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum","volume":"332","author":"Bendall","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jtcvs.2019.10.123","article-title":"Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors","volume":"159","author":"Jang","year":"2020","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib22","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in\u00a0vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2021.08.054_bib23","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/jco.2012.30.15_suppl.8520","article-title":"Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma","volume":"30","author":"McArthur","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12885-017-3382-6","article-title":"Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma","volume":"17","author":"Sneddon","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative,\u00a0phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib27","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0092-8674(00)81079-X","article-title":"Role\u00a0of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cell.2006.10.003","article-title":"The regulation of INK4\/ARF in cancer and aging","volume":"127","author":"Kim","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib30","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib31","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib33","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/bjc.2015.187","article-title":"Differential p16\/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients","volume":"113","author":"Jennings","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance [published correction appears in Nature. 2019;571:E10]","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2021.08.054_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e24326","article-title":"CDK4\/6 inhibitor and radiation therapy in malignant pleural mesothelioma","volume":"36","author":"Matsumoto","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497521016702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497521016702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:52:21Z","timestamp":1777377141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497521016702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0003497521016702"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2021.08.054","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.04.432811","asserted-by":"object"}]},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Cyclin Dependent Kinase 4\/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2021.08.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Society of Thoracic Surgeons","name":"copyright","label":"Copyright"}]}}